Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transmucosal Ketamine in Post Stroke Depression
NCT04876066Phase 1Unknown
- Sponsor
- West Virginia University
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by West Virginia University. Primary endpoints: Montgomery-Asberg Depression Rating Scale at 14 days and Montgomery-Asberg Depression Rating Scale - Self Report at 14 days. Status: unknown.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04876066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04876066.